98%
921
2 minutes
20
We investigated the anti-cholangiocarcinoma effect of α-mangostin from Garcinia mangostana pericarp extract (GM) in a human cholangiocarcinoma (CCA) cell line and a hamster CCA allograft model. In vitro, human CCA cells were treated with GM at various concentrations and for different time periods; then cell-cycle arrest and apoptosis were evaluated using flow cytometry, and metastatic potential with wound healing assays. In vivo, hamster allografts were treated with GM, gemcitabine (positive control) and a placebo (negative control) for 1 month; tumor weight and volume were then determined. Histopathological features and immunostaining (CK19 and PCNA) characteristics were examined by microscopy. The present study found that α-mangostin could: inhibit CCA cell proliferation by inducing apoptosis through the mitochondrial pathway; induce G1 cell-cycle arrest; and inhibit metastasis. Moreover, α-mangostin could inhibit CCA growth, i.e. reduce tumor mass (weight and size) and alter CCA pathology, as evidenced by reduced positive staining for CK19 and PCNA. The present study thus suggested that α-mangostin is a promising anti-CCA compound whose ready availability in tropical countries might indicate use for prevention and treatment of CCA.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464488 | PMC |
http://dx.doi.org/10.22034/APJCP.2017.18.3.707 | DOI Listing |
Adv Clin Exp Med
September 2025
Center for Translational Medicine, Faculty of Medicine, Khon Kaen University, Thailand.
Background: Late diagnosis and chemotherapy resistance, particularly to 5-fluorouracil (5-FU), contribute to the low survival rate in cholangiocarcinoma (CCA) patients. Identifying relevant genes and pathways, as well as novel targeted molecules, is crucial to overcoming 5-FU resistance and improving treatment outcomes for CCA patients.
Objectives: This study aimed to determine the potential molecules associated with 5-FU resistance in CCA cells.
Phytomedicine
August 2025
Department of Pathology & Cancer Research Center, Yanbian University Medical College, Yanji, China; Key Laboratory of Pathobiology, State Ethnic Affairs Commission & Central Laboratory, Yanbian University Hospital,Yanji, China. Electronic address:
Background: Cholangiocarcinoma (CCA) , an aggressive cancer often detected late, carries a grim prognosis. 2',4'-Dihydroxychalcone (2',4'-DHC), a flavonoid monomer isolated from Empetrum nigrum, has demonstrated notable anti-tumor activity in multiple cancer types. However, its therapeutic mechanism in cholangiocarcinoma remains poorly understood, especially regarding the regulation of ferroptosis, a mechanism that has not yet been fully elucidated in this disease.
View Article and Find Full Text PDFBr J Cancer
September 2025
Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China.
Background: Cholangiocarcinoma (CCA) is a rare and highly aggressive malignancy originating in the bile ducts. Owing to limitations involving pathological sampling, the clinical differentiation of CCA from benign biliary diseases remains challenging. This study aimed to evaluate the differences between the bile lipidomes of CCA patients and those of patients with benign disease to develop a bile lipid classifier that can help to differentiate CCA from benign conditions.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
September 2025
Department of Physical Examination Center, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Background: The aging problem is a significant issue and challenge currently faced by the whole world. Hyperhomocysteinemia (HHcy) is a common phenomenon among the older adult. Increasing evidence suggests a link between HHcy and multiple systemic issues in the older adult-related diseases.
View Article and Find Full Text PDFbioRxiv
August 2025
Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA USA.
Hepatocytes (HCs), which share a developmental origin with cholangiocytes (CCs), have the capacity to undergo reparative reprogramming into CCs in response to liver injury and, under specific conditions, can also transform malignantly into cholangiocarcinoma (CCA). However, the molecular mechanisms governing HC plasticity in liver diseases remain poorly understood. In this study, we investigated the role of , an oncofetal transcription factor, in both malignant and regenerative HC fate transitions toward the biliary lineage.
View Article and Find Full Text PDF